Aveanna Healthcare Holdings, Inc. Stock Price, News & Analysis

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH) will release its first quarter results on May 11, 2023, before market opening. A conference call is scheduled for 10:00 a.m. (ET) on the same day, allowing investors to engage with the company directly. Participants can access the live call at 1-877-407-0789 (US) or 1-201-689-8562 (international), with a replay available until May 18, 2023, using passcode 13737306. Aveanna provides a range of healthcare services across 33 states, including nursing, rehabilitation, and home health services, aimed at delivering quality care at lower costs compared to hospitalization. Interested parties can also join a live webcast via the company’s Investor Relations website.

Aveanna Healthcare Holdings (AVAH) reported Q4 2022 revenue of $451.1 million, up 9.0% from Q4 2021. Gross margin increased 3.5% to $128.8 million, but net loss widened to $237.8 million due to significant non-cash goodwill impairment charges. Adjusted EBITDA fell 35% to $29.7 million, marking 6.6% of revenue. For FY 2022, revenue rose 6.5% to $1.78 billion while net loss climbed to $662 million. The company forecasts revenue of at least $1.84 billion and adjusted EBITDA of at least $130 million for 2023, despite operational challenges.

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH) will announce its fourth quarter and full year results on March 16, 2023, before market open. A conference call will follow at 10 a.m. Eastern Time, where investors can join via phone or webcast. The replay will be available post-call until March 23, 2023. Aveanna provides diverse healthcare services across 33 states, including nursing and rehabilitation services for children and adults. The company aims to offer high-quality, cost-effective alternatives to prolonged hospital stays.

Aveanna Healthcare Holdings (NASDAQ: AVAH) announces the retirement of CEO Tony Strange, effective December 31, 2022. Jeff S. Shaner, the current COO, will take over as CEO. Tony's leadership was crucial for Aveanna's growth over the past five years, particularly during the pandemic. The company reaffirms its 2022 guidance of at least $1,782 million in revenue and $128 million in adjusted EBITDA, indicating stability despite leadership changes.

Aveanna Healthcare Holdings (NASDAQ: AVAH) reported Q3 2022 revenue of $443.0 million, a 7.7% increase from $411.3 million in Q3 2021, driven by Private Duty Services and Home Health & Hospice segments. However, gross margin decreased to 30.4% from 34.0% year-over-year. Net income rose to $24.3 million, with net income per diluted share at $0.13, but adjusted net loss per diluted share was $0.03. Full-year revenue guidance was revised down to $1,782 million, with Adjusted EBITDA expected at least $128 million, below previous guidance of $150 million.

Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH) announced it will release its third quarter financial results on November 9, 2022, after market close. A conference call will follow on November 10, 2022, at 10:00 a.m. ET to discuss the results. Investors can join the call by dialing 1-877-407-0789 or access a webcast via the Investor Relations section of Aveanna's website. The replay of the call will be available until November 17, 2022. Aveanna provides a wide range of healthcare services across 33 states, focusing on quality care at lower costs.

Aveanna Healthcare Holdings (NASDAQ: AVAH) reported Q2 2022 revenue of $443 million, up from $436.1 million in Q2 2021, marking a 1.6% increase. However, the company faced significant challenges, including a net loss of $473.9 million compared to a net income of $1.3 million last year, primarily due to a $470.2 million goodwill impairment. Adjusted EBITDA decreased to $37 million, or 8.3% of revenue, down from 11.2% in Q2 2021. Aveanna remains optimistic about future growth opportunities despite ongoing labor market challenges and inflationary wage pressures.

Aveanna Healthcare Holdings (NASDAQ: AVAH) has announced preliminary results for Q2 2022, indicating weaker performance due to ongoing labor market challenges and inflationary wage pressures. The company anticipates Adjusted EBITDA in the range of $36 million to $39 million, significantly lower than prior expectations. Revenue guidance has been revised down to at least $1,785 million, from an earlier estimate of $1,890 million to $1,920 million. Despite these challenges, Aveanna maintains liquidity with $12 million in cash and $167 million available under its revolving credit facility.

Aveanna Healthcare reported a revenue increase of 8.0% to $450.5 million for Q1 2022, driven by acquisitions of Comfort Care and Accredited. Gross margin rose 10.0% to $144.8 million, while net income surged to $25.3 million, bolstered by a $38.3 million non-cash gain on interest rate hedges. However, adjusted EBITDA fell 13.2% to $38.0 million. Operating income decreased 51.3% to $13.8 million, reflecting increased corporate expenses and a decline in field contribution. Aveanna aims to expand services despite ongoing labor and operational challenges.